The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
Official Title: Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA, An Observational Multicenter Study
Study ID: NCT04264767
Brief Summary: Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue. This study is being performed as part of the development process of the Pan Cancer EpiCheck test which includes the identification of different methylation profiles in various cancer types and healthy controls.
Detailed Description: The aim of this study is to characterize methylation patterns that will distinguish cancer from normal samples and will be able to recognize the origin of the cancer by collecting cfDNA (circulating free DNA) from blood samples collected from patients with a new diagnosis of cancer and from healthy volunteers who do not have diagnosis or history of cancer. Identifying those methylation patterns may assist in the development of blood test that will be able to detect the presence and the origin of wide range of human cancers
Minimum Age: 22 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Los Angeles Hematology Oncology Medical Group - Wilson Terrace, Glendale, California, United States
Los Angeles Hematology Oncology Medical Group - Good Samaritan Medical Offices, Los Angeles, California, United States
Sourasky Medical Center, Tel Aviv, , Israel
Name: Shmulik Adler
Affiliation: Nucleix Ltd.
Role: STUDY_DIRECTOR